SLC26A9 and cystic fibrosis: We found that 8 of the 10 previously published CF lung modifiers that passed GENDULF step 1 also passed GENDULF step 2; the two exceptions (SFTPA1, SLC26A9) had no expression measurements in the case–control data and hence could not possibly be detected at step 2.